Tenofovir alafenamide is a nucleoside analog reverse transcriptase inhibitor prodrug used for chronic hepatitis B treatment, marketed as VEMLIDY in this label. It is converted intracellularly to tenofovir diphosphate, which inhibits HBV reverse transcriptase and causes viral DNA chain termination. U.S. initial approval in this label is 2015.
Merck announced Phase 3 trial results for its investigational once-daily, two-drug HIV regimen doravirine/islatravir at CROI 2026, demonstrating non-inferiority to standard treatment in treatment-naïve adults with viral suppression rates of 91.8% at Week 48.
A once-daily single-tablet combination of bictegravir and lenacapavir demonstrated non-inferiority to existing HIV treatments in Phase 3 trials, offering simplified treatment for people living with HIV who are virologically suppressed.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05979311 |
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy |
ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05652478 |
Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study |
RECRUITING | PHASE2 |
| NCT05467553 |
A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection |
UNKNOWN | PHASE2 |
| NCT05453448 |
The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study |
COMPLETED | NA |
| NCT05423834 |
Chronic Kidney Disease Progression in Chronic Hepatitis B Patients on Tenofovir Alafenamide (TAF) Versus Entecavir |
ACTIVE_NOT_RECRUITING | |
| NCT05275023 |
An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants |
COMPLETED | PHASE2 |
| NCT05001672 |
The Efficacy of Prophylactic TAF for HBsAg-positive Patients Receiving bDMARDs |
NOT_YET_RECRUITING | PHASE4 |
| NCT04939441 |
Regression of Liver Fibrosis by Tenofovir Alafenamide (TAF) |
UNKNOWN | PHASE4 |
| NCT04937881 |
PK of TAF and TDF for PrEP in Pregnant and Postpartum Women |
COMPLETED | PHASE3 |
| NCT04891770 |
Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB) |
COMPLETED | PHASE2 |
